Preparation, characterization, in vivo and in vitro studies of arsenic trioxide Mg-Fe ferrite magnetic nanoparticles.
OBJECTIVE
MgFe(2)O(4) magnetic nanoparticle composed of As(2)O(3) (As(2)O(3)-MNPs) were prepared and their in vitro and in vivo characteristics were studied.


METHODS
The solvent-displacement method was applied for preparation of the nanoparticle using Poly-D,L-lactic-co-glycolic acid(PLGA). The characteristics studies of the products included magnetic response, morphology (transmission electron microscopy and scanning electron microscopy), entrapment efficiency, drug loading, particle sizes, zeta potential, in vitro drug release and tissue magnetic targeting. Nanoparticle cytotoxicity to Saos-2 cells was investigated using the MTT assay. To guide the external magnetic field in the liver, the concentration of As(2)O(3) in the liver and kidney was measured using an atomic fluorescence spectrometer after injecting As(2)O(3)-MNPs into the caudal veins of mice.


RESULTS
The As(2)O(3)-MNPs were approximately spherical. The average diameter, drug loading, entrapment efficiency and zeta potential of As(2)O(3)-MNPs were 109.9 nm, 10.08%, 82.16%, and -14.33 mV, respectively. The specific saturation magnetism was 8.65 emu/g. In vivo, the concentration of As(2)O(3) in the liver was significantly higher than that in the non-magnetic group. While the concentration of As(2)O(3) in the kidney was lower than that in the non-magnetic group. The C(max) in liver tissue in the magnetic group was 30.65 microg/g, which was 4.17 times the drug concentration in the same group in kidney tissue (7.35 microg/g) and 2.88 times the concentration of drug (10.66 microg/g) in the liver tissue of the non-magnetic group.


CONCLUSIONS
The PLGA polymer-loaded magnetic nanoparticle composed of arsenic trioxide can be magnetically targeted well and applied in biomedicine.
Yang
Guo-fu
GF
Department of Orthopaedics, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
Li
Xiang-hui
XH
Zhao
Zhe
Z
Wang
Wen-bo
WB
D000818:Animals; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004337:Drug Carriers; D005290:Ferric Compounds; D006016:Glycolates; D007501:Iron; D007668:Kidney / Q000166:cytology / Q000378:metabolism; D019344:Lactic Acid; D008099:Liver / Q000166:cytology / Q000378:metabolism; D008274:Magnesium; D008280:Magnetics; D053768:Metal Nanoparticles; D051379:Mice; D010087:Oxides / Q000008:administration & dosage*; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
D001152:Arsenicals; D004337:Drug Carriers; D005290:Ferric Compounds; D006016:Glycolates; D010087:Oxides; C001215:ferrite; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D007501:Iron; D008274:Magnesium; D000077237:Arsenic Trioxide